Drains Ablation Post Total Hip Arthroplasty : Search for the Least Painful Technique (TADDA)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Mylène BONNAIRE, Ms
- Phone Number: 8265 +3323288
- Email: mylene.bonnaire@chu-rouen.Fr
Study Locations
-
-
-
Rouen, France
- Rouen University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients admitted to the orthopedic surgery department for surgery for a total hip arthroplasty
- Signed inform consent form
Exclusion Criteria:
- Drain in non-aspirating mode at the time of medical ablation prescription
- Administration of analgesic III in the 12 hours preceding the inclusion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Drain ablation - Non Aspiration mode
Drain ablation will be done in non Aspiration mode
|
drain ablation will be done in Aspiration mode or in non Aspiration mode
|
|
Other: Drain ablation - Aspiration mode
Drain ablation will be done in Aspiration mode
|
drain ablation will be done in Aspiration mode or in non Aspiration mode
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate the pain felt by the patients at the time of the removal of the drain, using the pain visual analogue scale
Time Frame: 20 minutes
|
pain will be measured using a visual analogic scale from 0 (for no pain) to 10 (fo maximum pain)
|
20 minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Presence of haematoma after ablation
Time Frame: Day 2 post ablation
|
Presence or absence of haematoma will be visually checked
|
Day 2 post ablation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mylène BONNAIRE, University Hospital, Rouen
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2016/382/HP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.